Loading
Celularity Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 17 Jan 2024.
Celularity Inc: what insiders have been doing
Celularity Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, 22 filings were filed, from 7 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Compared with its exchange (5,811 companies, median 19 filings), a count of 22 filings is above the norm. Our records for Celularity Inc go back to 2021, with 5 purchases and 1 sale on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 26.6 m USD and net income of -91.7 m USD.
No insider has bought Celularity Inc shares on the open market in the past twelve months. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
113
Thresholds
n/a
Buy Volume
€6M
5 ops. · all time
Sell Volume
n/a
1 ops. · all time
Since the insiders bought
- -20.4%Entry US$2.89 · Close at T+365 US$2.30
- +7.7%Entry US$2.35 · Close at T+365 US$2.53
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.69
Analyst consensus
Income statement
RevenueUS$26.6M
Gross profitUS$6.5M24% margin
EBITDA-US$77.7M-293% margin
Net income-US$91.7M-345.4% margin
Valuation
Beta0.54
Balance sheet & cash
Market capUS$19.9M
Total debtUS$40.9M
Free Cash Flow-US$13.3M
Profitability & ownership
ROA-30.9%
% insiders37.2%
% institutions12.4%
Last declaration on 15 April 2026
Declarations113 total
821 shares0Class A Common StockSEC:0001493152-26-016834:0
1,641 shares0Class A Common StockSEC:0001493152-26-016833:0
3,281 shares0Class A Common StockSEC:0001493152-26-016832:0
30,000 shares0Class A Common StockSEC:0001493152-26-002427:0
20,385 shares0Class A Common StockSEC:0001493152-26-002425:0
19,231 shares0Class A Common StockSEC:0001493152-26-002424:0
28,847 shares0Class A Common StockSEC:0001493152-26-002423:0
19,231 shares0Class A Common StockSEC:0001493152-26-002303:0
28,847 shares0Class A Common StockSEC:0001493152-26-002300:0
20,385 shares0Class A Common StockSEC:0001493152-26-002298:0
30,000 shares0Class A Common StockSEC:0001493152-26-002297:0
125,000 shares0Class A Common StockSEC:0001493152-25-029618:0
125,000 shares0Class A Common StockSEC:0001493152-25-029615:0
125,000 shares0Class A Common StockSEC:0001493152-25-029617:0
125,000 shares0Class A Common StockSEC:0001493152-25-029614:0
67,416 shares0Class A Common StockSEC:0001493152-25-028787:0
67,416 shares0Class A Common StockSEC:0001493152-25-028780:0
67,416 shares0Class A Common StockSEC:0001493152-25-028778:0
61,539 shares0Class A Common StockSEC:0001493152-25-024634:0
3,699 shares0Class A Common StockSEC:0001493152-25-024633:0
44,379 shares0Class A Common StockSEC:0001493152-25-024631:0
47,042 shares0Class A Common StockSEC:0001493152-25-024630:0
3,281 shares0Class A Common StockSEC:0001641172-25-013629:0
360 shares@ US$1.642.4% of flowClass A Common StockSEC:0001641172-25-004820:1
1,025 shares0Class A Common StockSEC:0001641172-25-004820:0
25 of 113 declarations
About Celularity Inc
Celularity Inc. is a biotechnology and regenerative medicine company listed on the Nasdaq in the United States under the ticker CELU. For investors, it is best understood as a speculative small-cap biotech whose value proposition is built around placental-derived biology. The company now positions itself as a longevity-focused cellular medicine platform, combining clinical-stage cell therapy development with a commercial biomaterials business derived from postpartum placenta. ([celularity.com](https://celularity.com/celularity-announces-filing-of-form-10-k-regains-nasdaq-compliance-and-highlights-continued-strategic-transformation/?utm_source=openai))
The company’s roots trace back to Anthrogenesis, founded in 1998, followed by a merger with Celgene in 2002 and the spin-out that created Celularity in 2017. Celularity became a public company in 2021. Its current headquarters are in Florham Park, New Jersey, although older corporate materials also reference Warren, New Jersey during an earlier phase of facility development. ([celularity.com](https://celularity.com/about/?utm_source=openai))
Read moreShow less
Operationally, Celularity is built around two main business lines. First, it commercializes or monetizes placental biomaterials used in wound care and tissue repair applications. Second, it develops off-the-shelf, cryopreserved allogeneic cell therapies derived from the postpartum placenta, including natural killer (NK) cells, engineered T cells such as CAR-T constructs, and mesenchymal-like stromal cells. The company highlights an integrated manufacturing platform and a 150,000-square-foot facility dedicated to translational research and cellular medicine production. ([celularity.com](https://celularity.com/?utm_source=openai))
From a competitive standpoint, Celularity is trying to differentiate itself through a scalable manufacturing model and a ready-to-use product concept that avoids some of the logistical complexity of autologous cell therapies. That said, the company operates in a highly competitive and capital-intensive environment where success depends on clinical validation, manufacturing quality, regulatory execution, and financing discipline. Its development programs target oncology, infectious disease, degenerative disease, and biology of aging, which keeps the opportunity set broad but also scientifically demanding. ([celularity.com](https://celularity.com/?utm_source=openai))
Recent corporate developments suggest a deliberate strategic reset. In May 2026, Celularity announced that it had filed its Form 10-K and regained compliance with Nasdaq listing requirements after a delayed filing. The company also closed a transaction with NexGel that monetizes part of its biomaterials portfolio, entered a strategic license deal that could generate up to $35 million in upfront and milestone-related value, and received $12.2 million from the sale of unused New Jersey net operating losses and R&D tax credits. It additionally completed financing transactions to support ongoing operations and strategic initiatives. Taken together, these moves indicate a company focused on strengthening liquidity, sharpening its portfolio, and concentrating resources on its longevity-oriented therapeutic pipeline. ([celularity.com](https://celularity.com/celularity-announces-filing-of-form-10-k-regains-nasdaq-compliance-and-highlights-continued-strategic-transformation/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
